育龄期乳腺癌女性患者伴病态肥胖的多学科诊疗模式

金瑶,董梅

中国药学杂志 ›› 2018, Vol. 53 ›› Issue (13) : 1130-1136.

PDF(1768 KB)
中国药学杂志
PDF(1768 KB)
中国药学杂志 ›› 2018, Vol. 53 ›› Issue (13) : 1130-1136. DOI: 10.11669/cpj.2018.13.017
论著

育龄期乳腺癌女性患者伴病态肥胖的多学科诊疗模式

  • 金瑶,董梅*
作者信息 +

MDT Model of a Breast Cancer Patient at Reproductive Age with Morbid Obesity

  • JIN Yao, DONG Mei*
Author information +
文章历史 +

摘要

目的 探讨临床药师参与肿瘤患者多学科诊疗的工作模式。方法 乳腺肿瘤内科医生、影像科医生、内分泌科医生和临床药师通过对育龄期乳腺癌伴病态肥胖的患者开展多学科协作诊疗,从肥胖原因、生育问题、抗肿瘤药物用量及激素类药物应用4个方面进行探讨,临床药师对患者进行用药风险评估,并参与到患者整个抗肿瘤治疗过程中。结果 经多学科讨论确定患者治疗方案及药物应用,患者顺利完成第一周期抗肿瘤治疗,未出现严重不良反应,提示临床药师在肿瘤多学科团队中的作用。结论 作为多学科团队重要成员之一,临床药师利用药学优势,与各学科医务工作者共同合作,初步形成了肿瘤患者多学科协作诊疗的工作模式。

Abstract

OBJECTIVE To explore the working mode of clinical pharmacists participating in multidisciplinary team (MDT) for cancer patients.METHODS A breast cancer physician leaded the team, comprised of an imageology specialist, an endocrinology specialist and a clinical pharmacist carried on the multidisciplinary discussions of a breast cancer patient at reproductive age with morbid obesity, focusing on the four aspects of morbid obesity, infertility, chemotherapeutic doses and application of dexamethasone. Clinical pharmacist evaluated the risk of medication in the patient and participated in the entire process of anti-tumor therapy.RESULTS After multidisciplinary discussions, we determined the patient treatments and drug applications, the patient successfully completed the first cycle of anti-tumor therapy with no serious adverse reactions.CONCLUSION As one of the important members of multidisciplinary team, the clinical pharmacist could cooperate with other physicians by taking the advantages of pharmacy, and initially could form the working mode of multidisciplinary diagnosis and treatments of cancer patients.

关键词

乳腺癌 / 病态肥胖 / 多学科团队 / 临床药师

Key words

breast cancer / morbidly obese / multidisciplinary team / clinical pharmacist

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
金瑶,董梅. 育龄期乳腺癌女性患者伴病态肥胖的多学科诊疗模式[J]. 中国药学杂志, 2018, 53(13): 1130-1136 https://doi.org/10.11669/cpj.2018.13.017
JIN Yao, DONG Mei. MDT Model of a Breast Cancer Patient at Reproductive Age with Morbid Obesity[J]. Chinese Pharmaceutical Journal, 2018, 53(13): 1130-1136 https://doi.org/10.11669/cpj.2018.13.017
中图分类号： R952   

参考文献

[1] PERGOLA G D, SILVESTRIS F. Obesity as a major risk factor for cancer[J]. J Obesity, 2013, 2013(13):291546.
[2] WANG W J. Report of cancer incidence and mortality in China, 2016[J/OL]. J Clin Med Liter(Elec Ed)(临床医药文献电子杂志), 2017, 4(19):3604.
[3] ANDERS C K, JOHNSON R, LITTON J, et al. Breast cancer before age 40 years[J]. Semin Oncol, 2009, 36(3):237-249.
[4] MCCRAY D K, SIMPSON A B, FLYCKT R, et al. Fertility in women of reproductive age after breast cancer treatment: practice patterns and outcomes[J]. Annals Surg Oncol, 2016, 23(10):1-7.
[5] BINES J, OLESKE D M, COBLEIGH M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. J Clin Oncol Off J Am Society Clin Oncol, 1996, 14(5):1718-1729.
[6] AKDUMAN A T, OZERKAN K, ZIK B, et al. Effect of tamoxifen on ovarian reserve: a randomized controlled assessor-blind trial in a mouse model[J]. J Turkish German Gynecol Assoc, 2014, 15(4):228-232.
[7] National Comprehensive Cancer Network[Z]. 2016. www. nccnorg. Accessed Feb 16, 2016.
[8] SHAH S, DOWELL J, GREENE S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting[J]. Ann Pharm, 2006, 40(9):1527-1533.
[9] KHANAL S, POUDEL A K, PALAIAN S. Oncology pharmacy practice in a teaching hospital in nepal[J]. J Oncol Pharm Pract, 2010, 16(2):75-79.
[10] BINES J, OLESKE D M, COBLEIGH M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. Matuvitas, 1996,25(2):156-157.
[11] BEN-AHARON I, BAR-JOSEPH H, TZARFATY G, et al. Doxorubicin-induced ovarian toxicity[J]. Rep Biol Endocrinol, 2010, 8(1):1-7.
[12] MEIROW D, LEWIS H, NUGENT D, et al. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool[J]. Human Reprod, 1999, 14(7):1903-1907.
[13] REH A, OKTEM O, OKTAY K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers[J]. Fertility & Sterility, 2008, 90(5):1635-1639.
[14] BARJOSEPH H, BENAHARON I, RIZEL S, et al. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes[J]. Reprod Tox, 2010, 30(4):566-572.
[15] TING A Y, PETROFF B K. Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat[J]. J Assisted Reprod Genetics, 2010, 27(11):591-597.
[16] BAR-JOSEPH H, BEN-AHARON I, TZABARI M, et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels[J]. PLoS One, 2011, 6(9):e23492.
[17] TARUMI W, SUZUKI N, TAKAHASHI N, et al. Ovarian toxicity of paclitaxel and effect on fertility in the rat[J]. J Obstet Gynaecol Res, 2009, 35(3):414-420.
[18] FU X W, SHI W Q, ZHANG Q J, et al. Positive effects of taxol pretreatment on morphology, distribution and ultrastructure of mitochondria and lipid droplets in vitrification of in vitro matured porcine oocytes[J]. Animal Reprod Sci, 2009, 115(1):158-168.
[19] SILVA C, CARAMELO O, ALMEIDA-SANTOS T, et al. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and Meta-analysis[J]. Human Reprod, 2016, 31(12):2737-2749.
[20] SAWYER M, RATAIN M J. Body surface area as a determinant of pharmacokinetics and drug dosing[J]. Investigational New Drugs, 2001, 19(2):171-177.
[21] DOOLEY M J, POOLE S G. Poor correlation between body surface area and glomerular filtration rate[J]. Cancer Chemother Pharm, 2000, 46(6):523-526.
[22] GRIGGS J, MANGU P, TEMIN S, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline[J]. J Oncol Pract, 2012, 8(4):59-61.
[23] ROILA F, MOLASSIOTIS A, HERRSTEDT J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients[J]. Annal Oncol, 2016, 27(Suppl 5):v119-v133.
[24] YU S Y, YIN J L, QIN S K, et al. Guidelines for the prevention and treatment of vomiting related to cancer treatment (2014 Edition)[J]. Chin Clin Oncol(临床肿瘤学杂志), 2014(3):263-273.
[25] CELIO L, BONIZZONI E, BAJETTA E, et al. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase Ⅲ trials[J]. Support Care Cancer, 2013,21(2):565-573.
[26] ZHANG L, TAN L, LU J. The expert consensus of off-labeled drug uses[J]. Adv Drug React J(药物不良反应杂志), 2015,17(2):101-103.
[27] NI G H, ZHANG J, ZHENG F T. Status and trends of Chinese obesity epidemic[J]. Food Nutrit China(中国食物与营养), 2013,19(10):70-74.
[28] GATHIRUA-MWANGI W G, SONG Y, MONAHAN P, et al. Associations of Metabolic syndrome and C‐reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES Ⅲ[J/OL]. International J Cancer, [2018-2-27]. https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31344.
[29] DU B D, DU B E. A formula to estimate the approximate surface area if height and weight be known[J]. Nutrition, 1916, 5(5):303-311.
[30] PORTER D J, WILSON M. Effect of capping chemotherapy dose on chemotherapy effect in morbidly obese women with breast cancer[J]. J Clin Oncol, 2013,31(15):1081.
[31] MADAMAS Y, SAWKA C A, FRANSSEN E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer[J]. Breast Cancer Res Treat, 2001, 66(2):123-133.
[32] ABDAH-BORTNYAK R, TSALIC M, HAIM N. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability[J]. Med Oncol, 2003, 20(4):363-368.
[33] LOPES-SERRAO M D, USSERY S M, SHAH S R. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing[J]. J Oncol Practice, 2011, 7(1):13-17.
[34] ROSNER G L, HARGIS J B, HOLLIS D R, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541[J]. J Clin Oncol, 1996, 14(11):3000-3008.
[35] COLLEONI M, LI S, GELBER R D, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index[J]. Lancet, 2005, 366(9491):1108-1110.
[36] GEORGIADIS M S, STEINBERG S M, HANKINS L A, et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer[J]. Jnci J Nat Cancer Inst, 1995, 87(5):361-366.
[37] POIKONEN P, BLOMAVIST C, JOENSUU H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area[J]. Acta Oncol, 2001, 40(1):67-71.
[38] GRIGGS J J, SORBERO M E, LYMAN G H. Undertreatment of obese women receiving breast cancer chemotherapy[J]. Arch Inter Med, 2005, 165(11):1267-1273.
[39] HOURDEQUIN K C, SCHPERO W L, MCKENNA D R, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and Meta-analysis[J]. Anna Oncol, 2013, 24(12):2952-2962.
[40] WANG K, GUO X. Present situation and prospect of the clinical pharmaceutical work in our hospital[J]. China Mod Med(中国当代医药), 2012,19(2):163-164.
[41] HU X L, ZHAN S P, WANG Y, et al. Polypharmacy management and pharmaceutical care of clinical pharmacists participating in the team of comprehensive geriatric assessment[J]. Chin Pharm J(中国药学杂志), 2017, 52(4):323-326.
[42] JIAN L Y, HE X J. Exploration of hospital pharmacy tendency in future[J]. Chin J Hosp Pharm(中国医院药学杂志), 2015, 35(20):1803-1806.
[43] LIU J Y, HE Y Y, JIANG A H, et al. Practice and analysis of clinical pharmacists participating in consultation[J]. Chin J Clin Rat Drug Use(临床合理用药杂志), 2017, 10(6):99-100.
[44] GUAN Z S, ZHOU X T. Perspectives on clinical pharmacists′ participating in consultation on the use of antibiotics in 227 cases[J]. J China Pharm(中国药房), 2009,20(17):1358-1360.
[45] LIAO Y, WEI N, PAN H M. Case analysis of clinical consultation of special grade[J]. Chin J Hosp Pharm(中国医院药学杂志), 2014, 34(4):315-318.
[46] XIE H, MA Z L, CHEN Z X, et al. Role and work mode of clinical pharmacists in the multidisciplinary pain management team[J]. Pharm Clin Res(药学与临床研究), 2015(3):331-336.
[47] OCVIRK J, BOC M, REBERSEK M, et al. Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanoma[J]. Radiol Oncol, 2009, 43(2):120-125.
[48] GOLDSPIEL B R, DECHRISTOFORO R, DANIELS C E. A continuous-improvement approach for reducing the number of chemotherapy-related medication errors[J]. Am J Healt-system Phar, 2000,57(Suppl 4):S4-S9.
[49] LIU M, YAN J Q, ZHANG Y, et al. Role and thinking of pharmacists in pharmaceutical affairs management at cancer hospital and quality control based on new health care reform background[J]. Chin Pharm J(中国药学杂志), 2018, 53(2):154-158.
PDF(1768 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉